Thomas Fulton Wilson McKillop

Former Chief Executive Officer at AstraZeneca Plc

Thomas Fulton Wilson McKillop

Thomas Fulton Wilson McKillop

Former Chief Executive Officer at AstraZeneca Plc

Overview
Career Highlights

The Science Council
European Federation Of Pharmaceutical Industries And Associations
Society of Chemical Industry

RelSci Relationships

918

Number of Boards

15

Birthday

03/19/1943

Age

74

Number of Awards

1

Relationships
RelSci Relationships are individuals Thomas Fulton Wilson McKillop likely has professional access to. A relationship does not necessarily indicate a personal connection.

Former Executive Vice President, Pharmaceutical Operations at Eli Lilly & Company

Relationship likelihood: Strong

Vice Chairman at UCB Pharma SA - Belgium

Relationship likelihood: Strong

Director, Division of Allergy & Immunology at Harvard University - Beth Israel Deaconess Medical Center at Harvard Medical School

Relationship likelihood: Strong

Former Chief Executive Officer at Pierre Fabre SA

Relationship likelihood: Strong

Corporate Director & General Counsel at Almirall SA

Relationship likelihood: Strong

President & Chief Executive Officer at Alere, Inc.

Relationship likelihood: Strong

Former Partner at KPMG LLP

Relationship likelihood: Strong

In-House Counsel at Alere Holdings Bermuda Ltd.

Relationship likelihood: Strong

Chief Executive Officer at Almirall SA

Relationship likelihood: Strong

Resident Scholar at American Enterprise Institute

Relationship likelihood: Strong

Paths to Thomas Fulton Wilson McKillop
Potential Connections via
Relationship Science
You
Thomas Fulton Wilson McKillop
Former Chief Executive Officer at AstraZeneca Plc
Education
PhD in Chemistry

Founded in 1451, Glasgow is the fourth-oldest university in the English-speaking world. Over the last five centuries and more, we’ve constantly worked to push the boundaries of what’s possible. We’ve fostered the talents of seven Nobel laureates, one Prime Minister and Scotland’s inaugural First Minister. We’ve welcomed Albert Einstein to give a lecture on the origins of the general theory of relativity. Scotland’s first female medical graduates completed their degrees here in 1894 and the world’s first ultrasound images of a foetus were published by Glasgow Professor Ian Donald in 1958. In 1840 we became the first university in the UK to appoint a Professor of Engineering, and in 1957, the first in Scotland to have an electronic computer. All of this means that if you choose to work or study here, you’ll be walking in the footsteps of some of the world’s most renowned innovators, from scientist Lord Kelvin and economist Adam Smith, to the pioneer of television John Logie Baird.

Memberships
Member
Current

The Royal Society is a self-governing Fellowship of many of the world’s most distinguished scientists drawn from all areas of science, engineering, and medicine. The Society’s fundamental purpose, reflected in its founding Charters of the 1660s, is to recognise, promote, and support excellence in science and to encourage the development and use of science for the benefit of humanity. The Society has played a part in some of the most fundamental, significant, and life-changing discoveries in scientific history and Royal Society scientists continue to make outstanding contributions to science in many research areas. The Royal Society is the national Academy of science in the UK, and its core is its Fellowship and Foreign Membership, supported by a dedicated staff in London and elsewhere. The Fellowship comprises the most eminent scientists of the UK, Ireland and the Commonwealth.

Member
Current

ERT today brings together up to 50 chief executives and chairmen of major multinational companies of European parentage, covering a wide range of industrial sectors. Individuals join at the personal invitation of existing Members, which confers on ERT membership a personal rather than corporate character. ERT Members meet twice a year, in person, at Plenary Sessions. At these Plenary Sessions, Members determine ERT’s work programme, set priorities and establish specialised Working Groups to work on them. Decisions are taken by consensus. The ERT Chairman, two vice-Chairmen, the former ERT Chairman and five other elected Members form the Steering Committee. The Steering Committee reviews ERT activities and makes recommendations to the Plenary Sessions. Each ERT Member nominates an Associate to act as a main point of liaison at working level and to help implement the decisions taken by Members. Much of the work is done by the Working Groups established by the Plenary Sessions. They are chaired by ERT Members and comprise Members, Associates and experts from the companies behind ERT Members. The Working Groups present proposals to the Plenary and take a leading role in the drafting of official ERT messages and positions. The Secretary General is in charge of a small Executive based in Brussels, which coordinates projects, acts as a contact point, provides administrative support and publishes the ERT reports.

Career History
Chief Executive Officer
Prior

Zeneca Group Plc used to develop & manufacture pharmaceutical products, agrochemicals and specialties chemicals. Its agrochemicals products include herbicides, insecticides and fungicides. The firm products were used by health care, agrochemical, paint, leather and imaging applications industries. The company was headquartered in London, UK.

President
2007 - 2011
Chief Executive Officer
1999 - 2005

AstraZeneca Plc is a holding company, which engages in the research, development and manufacture of pharmaceutical products. The company produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases. Its pipeline consists of azd 0156, medi 573, tagrisso bloom, durvalumab, selumetinib, lyparza polo, epanova, farxiga and brilinta. The company distributes its products under the following brands: Atacand, Crestor, Onglyza, Nexium, Entocort, Losec, Merrem/Meronem, Carbocaine, Citanest, Diprivan, Marcaine/Sensorcaine. AstraZeneca was founded on April 6, 1999 and is headquartered in London, the United Kingdom.

Boards & Committees
Member, Board of Directors
2013 - Current

At Alere, our mission is to empower individuals to take charge of their health under the supervision of their healthcare providers. We bring this vision to life by developing smart products that address broad, unmet needs and extend diagnosis from the lab, doctor’s office, and hospital to people’s homes. We also build educational health management solutions around these products, which make it easier than ever to personalize care. Our programs connect patients to information that yields diagnostic results, and our smart platforms give healthcare providers seamless and instant access to these results, supplying them with the information they need to make the best decisions. We believe that, when people are involved in their own care, they benefit from an improved quality of life. Our products and services lead to better health, less urgent medical interventions, fewer hospital visits, and reduced healthcare costs.

External Independent Director
2007 - Current

Almirall SA engages in the development, manufacture, storage, commercialization and sale of pharmaceutical and cosmetic products, as well as of the raw materials used in production. The company operates through the following segments: Marketing through Own Network, Marketing by Licensees, Research and Development Activity, Therapeutic Area of Dermatology in the United States, and Corporate Management and Results not assigned to Other Segments. Its products include treatments for respiratory, autoimmune, dermatological and gastrointestinal diseases. The company was founded in 1943 and is headquartered in Barcelona, Spain.

Non-Executive Director
Current

Theravectys SAS provides biotechnology research services. It is working on the development of a therapeutic vaccine against HIV. The company was founded on May 17, 2005 and is headquartered in Paris, France.

Non-Profit Donations & Grants

Learn how non-profit organizations benefit from RelSci
$100 - $499
2012

RECEIVE, HOLD, INVEST AND ADMINISTER PROPERTY AND TO MAKE EXPENDITURES TO OR FOR THE BENEFIT OF CALIFORNIA STATE UNIVERSITY, FRESNO.

Awards & Honors
2004
University of St. Andrews